Navigation Links
Tengion Provides Business Update and Reports Third Quarter 2012 Financial Results
Date:11/13/2012

WINSTON-SALEM, N.C., Nov. 13, 2012 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today reported its financial results for the third quarter ended September 30, 2012 and provided a business update.

"We are focused on enrolling the remaining four patients in the Phase 1 trial of our Neo-Urinary Conduit, which we hope to complete by year-end, and we are working aggressively to file the IND for our Neo-Kidney Augment during the first half of 2013," said John L. Miclot, President and Chief Executive Officer of Tengion. "We are dedicated to executing on our key program objectives and our successful $15 million private placement completed last month has provided us with sufficient funding to achieve these value creating milestones. We also recently received two Notices of Allowance from the USPTO for patent applications covering the novel technologies around the Neo-Urinary Conduit and Neo-Kidney Augment programs, which further solidify the breadth and strength of Tengion's novel technology and the expanding intellectual property portfolio around it."

Neo-Urinary Conduit Clinical Program UpdateTengion has implanted six patients in the ongoing Phase 1 clinical trial of its most advanced product candidate, the Neo-Urinary Conduit, for use in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy). The trial is an open-label, single-arm study, which is expected to enroll up to 10 patients.

In November 2012, Tengion announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 12/612,606, titled "Cell-Scaffold Constructs." The application includes compositional claims on the construct and cellular elements of the Neo-Urinary Conduit, as well as use claims covering this technology in additional clinical applications.

In October 2012, Tengion announced that two patients in the Phase 1 clinical trial of its Neo-
'/>"/>

SOURCE Tengion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
2. Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina
3. Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
4. New Resource Provides Herb Industry With Sources of Quality Specifications
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
7. Health Diagnostic Laboratory, Inc. Provides Largest Corporate Gift in Science Museum of Virginias History
8. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
9. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
10. Insmed Incorporated Provides Corporate Update
11. Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014 ... ) announced today that Medtronic, Inc. (NYSE: ... application to the U.S. Food and Drug Administration ... II implantable drug infusion system (including a ... Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... December 23, 2014 “Preparative & ... HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, ... & Agriculture) - Forecasts to 2019” provides a ... opportunities, current market trends, and strategies impacting the ... estimates and forecasts of the revenue and share ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... and Continuing Resolution Appropriations Act of 2015, which ... eligible to receive funding through the Congressionally Directed ... of Defense (DoD). The Hydrocephalus Association (HA), working ... is celebrating this victory for the over 1 ...
(Date:12/24/2014)... report expects global cell isolation and expansion market to ... carefully analyzed data about the vital drivers, restraints, trends, ... Copy of Report @ http://bit.ly/1yUxy0T , According ... will keep witnessing growth at an impressive CAGR during ... by rapid technological advancements, government funding and investments, and ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... want to start a business? And it's going to be ... usually comes first. Is it Biotech? Software? Before raising any ... this commercial idea is critical because it is most likely ... is this? Patentable? Copyrightable? Trade Secret? Can it be identified ...
... awarded two federal grants totaling more than $800,000 for ... biotechnology company, which develops high throughput screening tools for ... I and Phase II Small Business Innovation Research ... conduct millions of biochemical, genetic, or pharmacological tests in ...
... Wisconsin-Madison 's partnership with Google to digitize ... make one of the best historical collections in the ... months, the popular search engine company, in collaboration with ... will make books and rare documents currently available only ...
Cached Biology Technology:Starting a tech business? Step 1 is minding the intellectual property 2Starting a tech business? Step 1 is minding the intellectual property 3Grants worth $800,000 help BellBrook Labs develop products 2Google to place Wisconsin history online 2Google to place Wisconsin history online 3Google to place Wisconsin history online 4
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... running out of room to maneuver. As forests in ... human uses, populations of these arboreal leaf eaters, which depend ... isolated and at risk. But one type of sustainable agriculture, ... critical refuges and bridges between intact forests for the iconic ...
... lives in increasingly humanised landscapes, with limited food resources ... to Spanish researchers, food availability plays a secondary role ... allow wolves to remain in human-dominated environments in Galicia. ... lupus signatus ) varies greatly across the Iberian Peninsula ...
... July 11, 2012 Researchers at the Translational Genomics Research ... could lead to a less costly, less invasive and more ... CKD is a major complication of diabetes, high blood pressure ... is characterized by a progressive deterioration of the kidney,s ability ...
Cached Biology News:Down on the cacao farm: Sloths thrive at chocolate's source 2Down on the cacao farm: Sloths thrive at chocolate's source 3The Iberian wolf lives close to humans more for refuge than for prey 2TGen method isolates biospecimens for treatment of kidney disease 2
... Crotalus adamanteus venom Description: Phosphodiesterase ... used in studying nucleic acid ... It hydrolyzes 5'-mononucleotides from 3'-hydroxy-terminated ... Phosphodiesterase I cleaves ADP-ribosylated proteins ...
This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....
... is a recombinant Moloney murine leukemia ... Transcriptase is similar to MuLV reverse ... usage. MuLV reverse transcriptase is a ... single-stranded RNA as a template in ...
... F2α (8-iso-13,14-dihydro-15-keto PGF2α) is a metabolite ... in rabbits, monkeys and humans. 8-iso ... non-specific lipid peroxidation. In both humans ... converted primarily to metabolites having 2 ...
Biology Products: